Welcome to our dedicated page for LifeStance Health Group news (Ticker: $LFST), a resource for investors and traders seeking the latest updates and insights on LifeStance Health Group stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LifeStance Health Group's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LifeStance Health Group's position in the market.
LifeStance Health Group (NASDAQ: LFST), a leading provider of outpatient mental health care in the U.S., announced its participation in two upcoming investor conferences. CFO Dave Bourdon and VP of Finance and Investor Relations Monica Prokocki will attend the UBS Healthcare Services Cape Cod Summit on June 4, 2024, in Chatham, MA, and the Goldman Sachs 45th Annual Healthcare Conference on June 10, 2024, in Miami Beach, FL. While the Cape Cod event will not include presentations, the Goldman Sachs conference will feature a presentation at 10:00 a.m. ET, which will be webcast live and later available for replay on LifeStance’s Investor Relations website.
LifeStance Health Group announced the pricing of a secondary public offering of 20,000,000 shares at $6.25 per share. The underwriters have a 30-day option to purchase an additional 3,000,000 shares. Proceeds will go to the selling stockholders, with none to LifeStance. The offering is expected to close by May 24, 2024, subject to customary conditions. The transaction is facilitated by major financial institutions including Morgan Stanley and Goldman Sachs. The shelf registration statement was filed with the SEC and became effective on May 21, 2024.
LifeStance Health Group announced a secondary public offering of 20 million shares of common stock by certain stockholders. The underwriters are given a 30-day option to purchase an additional 3 million shares. LifeStance will not sell any shares or receive any proceeds from this offering. The offering is made under a shelf registration statement filed with the SEC on May 21, 2024. Morgan Stanley, Goldman Sachs & TPG Capital are the underwriters. The prospectus is available on the SEC's website.
LifeStance Health Group, Inc. (Nasdaq: LFST) reported strong financial results for Q1 2024, with a revenue increase of 19% to $300.4 million, driven by higher visit volumes and improved revenue per visit. The clinician base also grew by 15%, reaching 6,866 clinicians. The company posted a net loss of $21.1 million, attributed to stock-based compensation, and an Adjusted EBITDA of $27.7 million. LifeStance reiterated its full-year revenue guidance of $1.19 billion to $1.24 billion, raising Center Margin expectations to $353 to $373 million, and Adjusted EBITDA to $88 to $98 million. The company also expects to maintain positive Free Cash Flow for the year.